• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia.

作者信息

Teri L, Logsdon R G

机构信息

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle 98195, USA.

出版信息

J Geriatr Psychiatry Neurol. 1995 Oct;8 Suppl 1:S8-17. doi: 10.1177/089198879500800103.

DOI:10.1177/089198879500800103
PMID:8561844
Abstract

Selecting outcome measures that are both psychometrically sound and sensitive to change is a very important aspect of clinical outcome research. A variety of measures have been introduced in recent years to assess behavioral complications in dementia, but few have been adequately tested in clinical trials. This article provides a discussion of factors to consider in selecting measures, including psychometrics, item content, assessment source, and sensitivity to change. A review of behavioral and psychiatric measures for dementia patients is provided, including measures of general behavioral disturbance, and measures specifically developed for agitation and depression. Each measure's psychometric characteristics, prior use with demented patients, and strengths and weaknesses with regard to treatment outcome research is summarized. The importance of linking measures to the investigators' hypotheses is discussed, along with recommendations for evaluating and selecting outcome measures depending on the needs of the specific investigation.

摘要

相似文献

1
Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia.
J Geriatr Psychiatry Neurol. 1995 Oct;8 Suppl 1:S8-17. doi: 10.1177/089198879500800103.
2
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.评估药物制剂治疗痴呆行为和心理症状的疗效及安全性的量表。
J Clin Psychiatry. 2001;62 Suppl 21:19-22.
3
Agitation in the morning: symptom of depression in dementia?早晨的烦躁:痴呆症的抑郁症状?
Int J Geriatr Psychiatry. 2009 Apr;24(4):335-40. doi: 10.1002/gps.2108.
4
Reporting changes in scores on the Cohen-Mansfield agitation inventory subscales.报告科恩-曼斯菲尔德激越量表各分量表得分的变化情况。
J Clin Psychiatry. 2003 Jun;64(6):732; author reply 732. doi: 10.4088/jcp.v64n0618b.
5
Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers.痴呆的行为和心理症状:临床医生、研究人员及护理人员当前关注的焦点。
J Clin Psychiatry. 2001;62 Suppl 21:3-6.
6
Methodological issues in characterizing treatment response in demented patients with behavioral disturbances.
Int J Geriatr Psychiatry. 1997 May;12(5):537-47.
7
A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.抗抑郁试验中临床总体印象变化的比较性荟萃分析。
J Nerv Ment Dis. 2006 Nov;194(11):845-52. doi: 10.1097/01.nmd.0000244554.91259.27.
8
Risperidone for the treatment of behavioral and psychological symptoms of dementia.利培酮用于治疗痴呆的行为和心理症状。
J Clin Psychiatry. 2001;62 Suppl 21:29-32.
9
[Methodological and regulatory features of clinical trials for behavioral and psychological symptoms in the course of dementia].[痴呆病程中行为和心理症状临床试验的方法学与监管特征]
Ann Ist Super Sanita. 2003;39(2):267-74.
10
Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents.对用于儿童和青少年临床试验的自我报告疼痛强度测量工具的心理测量特性、可解释性和可行性的系统评价。
Pain. 2006 Nov;125(1-2):143-57. doi: 10.1016/j.pain.2006.05.006. Epub 2006 Jun 13.

引用本文的文献

1
Living well with stroke: design and methods for a randomized controlled trial of a psychosocial behavioral intervention for poststroke depression.卒中后良好生活:一项针对卒中后抑郁的社会心理行为干预随机对照试验的设计与方法
J Stroke Cerebrovasc Dis. 2008 May-Jun;17(3):109-15. doi: 10.1016/j.jstrokecerebrovasdis.2007.12.002.
2
EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.确切地说:卡巴拉汀可改善阿尔茨海默病中注意力缺陷以及情绪和行为症状的高发生率。
Int J Clin Pract. 2007 Jun;61(6):886-95. doi: 10.1111/j.1742-1241.2007.01387.x.